NOVATO, Calif., May 19, 2023 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company’s chief medical officer, will present at the 2023 Barclays -…Read More
Ultragenyx to Present at the 2023 Barclays Gene Editing Gene Therapy Summit
